- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01156298
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance (CHAMPIONS CONT)
Phase IV, Multi-center, Non-treatment, Observational, Registry Study to Determine Long Term Effects of AVONEX® Therapy on EDSS, MRI, QoL, and Cognition.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The primary objective of this study is to determine the impact of long term AVONEX® treatment on physical status, measured by expanded disability scale score (EDSS), of patients with Multiple Sclerosis (MS) after their first clinical event (clinically isolated syndrome) and Magnetic Resonance Imaging (MRI) consistent with MS.
Secondary objectives are to determine the impact of long term therapy with AVONEX® on the following:
a) MRI parameters- new or enlarging T2 lesions, T2 lesion volume, T1 lesion volume, brain parenchymal fraction (BPF) b) Quality of Life (QoL): Heath Status Questionnaire (SF-36) c) Symbol Digit Modality Test (SDMT)
2. To determine the long term impact of therapy on the following in patients treated at the onset of clinically isolated event (CIS)
- EDSS
- MRI parameters
- SF-36
SDMT
3. To determine early clinical and MRI predictors of disease progression.
Approximately 383 patients participated in CHAMPS, the original AVONEX® placebo trial, will be approached for study participation. The patient population will be divided into two cohorts.
Cohort 1: Patients that participated in CHAMPS and CHAMPIONS 10 will be approached for study participation at approximately twenty-four CHAMPIONS Continuation investigative sites.
Cohort 2: Patients that participated in CHAMPS will be located and approached for study participation. Patient that participated in CHAMPIONS 10 will not be excluded from Cohort 2. Efforts will be made to potentially locate patients through either the original CHAMPS investigative sites, through the Biogen Idec patient services database, and/or a third party (i.e., patient location service vendor) or some combination of the three. .
For both cohorts, public databases may be utilized for patient reported death.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
New York
-
Buffalo, New York, États-Unis, 14203
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Approximately 383 patients participated in CHAMPS, the original AVONEX® placebo trial, will be approached for study participation. The patient population will be divided into two cohorts.
Cohort 1: Patients that participated in CHAMPS and CHAMPIONS 10 will be approached for study participation at approximately twenty-four CHAMPIONS Continuation investigative sites. Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date. See Schedule of Assessments, section 12.
Cohort 2: Patients that participated in CHAMPS will be located and approached for s
La description
Inclusion Criteria:
Patients are eligible to be screened for this study if all of the following criteria are met:
- All patients must have been originally enrolled in CHAMPS, regardless of randomization arm. Only Cohort 1 patients must have been enrolled in CHAMPIONS 10.
- Willing and able to provide informed consent (Cohort 1), waiver of informed consent (Cohort 2), or reported patient death through public database search.
- Ability to read and write English (patient reported assessment tools are in English only).
Exclusion Criteria:
Candidates will be excluded from study screening if any of the following exclusion criteria exist:
- Patients not participating in the original CHAMPS study.
- Alternative diagnosis to MS discovered.
- Patient unwilling or unable to provide informed consent (Cohort 1) or waiver of informed consent (Cohort 2), as applicable.
- Any other reasons that, in the opinion of the Investigator (Cohort 1) or Patient Coordination Center (Cohort 2), the patient is determined to be unsuitable for enrollment into this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Cohort 1
Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS.
Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not.
Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation.
SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits.
A MRI will be performed each patient's 15 year anniversary date.
|
Cohort 2
Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS.
Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not.
Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
EDSS
Délai: yearly
|
yearly
|
MRI
Délai: last visit, 15 year anniversary
|
last visit, 15 year anniversary
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Quality of Life
Délai: year 1 & 5
|
year 1 & 5
|
Symbol Digit Modality Test
Délai: year 1 & 5
|
year 1 & 5
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 004-09-AVX
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .